^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    becotarug (JMT101)

    i
    Other names: JMT101
    Company:
    CSPC Pharma
    Drug class:
    EGFR inhibitor
    Related drugs:
    1m
    The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sir Run Run Shaw Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    1m
    Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases (clinicaltrials.gov)
    P3, N=200, Recruiting, Ming-Yuan Chen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    1m
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (clinicaltrials.gov)
    P2, N=59, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • docetaxel • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    1m
    A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fudan University
    New P2 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    1m
    Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (clinicaltrials.gov)
    P2, N=59, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • docetaxel • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Fudan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Erbitux (cetuximab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases (clinicaltrials.gov)
    P3, N=200, Not yet recruiting, Ming-Yuan Chen
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101) • vibecotamab (XmAb14045)
    2ms
    Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC (clinicaltrials.gov)
    P3, N=266, Recruiting, First Affiliated Hospital of Guangxi Medical University
    New P3 trial
    |
    cisplatin • gemcitabine • Tyvyt (sintilimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    Recent highlights and breakthroughs in immunotherapy for head and neck cancers. (PubMed, Curr Opin Oncol)
    Recent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Erbitux (cetuximab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Bavencio (avelumab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Padcev (enfortumab vedotin-ejfv) • Meiyouheng (becotatug vedotin) • ficerafusp alfa (BCA101) • petosemtamab (MCLA-158) • becotarug (JMT101) • izalontamab (SI-B001) • izalontamab brengitecan (BL-B01D1) • Cotelet (tagitanlimab)
    2ms
    Becotatug Vedotin: First Approval. (PubMed, Drugs)
    In October 2025, becotatug vedotin received its first approval in China for the treatment of adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) inhibitor therapy. This article summarizes the milestones in the development of becotatug vedotin leading to this first approval for nasopharyngeal cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    3ms
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    3ms
    Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Fudan University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)